Single-cell profiling defines the prognostic benefit of CD39


Journal

Communications biology
ISSN: 2399-3642
Titre abrégé: Commun Biol
Pays: England
ID NLM: 101719179

Informations de publication

Date de publication:
22 09 2021
Historique:
received: 09 08 2020
accepted: 12 08 2021
entrez: 23 9 2021
pubmed: 24 9 2021
medline: 15 12 2021
Statut: epublish

Résumé

Luminal-like breast cancer (BC) constitutes the majority of BC subtypes, but, differently from highly aggressive triple negative BC, is poorly infiltrated by the immune system. The quality of the immune infiltrate in luminal-like BCs has been poorly studied, thereby limiting further investigation of immunotherapeutic strategies. By using high-dimensional single-cell technologies, we identify heterogeneous behavior within the tissue-resident memory CD8+ T (Trm) cells infiltrating luminal-like tumors. A subset of CD127- CD39

Identifiants

pubmed: 34552178
doi: 10.1038/s42003-021-02595-z
pii: 10.1038/s42003-021-02595-z
pmc: PMC8458450
doi:

Substances chimiques

Apyrase EC 3.6.1.5
ENTPD1 protein, human EC 3.6.1.5

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1117

Commentaires et corrections

Type : ErratumIn

Informations de copyright

© 2021. The Author(s).

Références

Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: the next generation. Cell 144, 646–674 (2011).
pubmed: 21376230 doi: 10.1016/j.cell.2011.02.013
Sorlie, T. et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc. Natl Acad. Sci. USA 100, 8418–8423 (2003).
pubmed: 12829800 pmcid: 166244 doi: 10.1073/pnas.0932692100
Xu, J. et al. Elevated tumor mutation burden and immunogenic activity in patients with hormone receptor-negative or human epidermal growth factor receptor 2-positive breast cancer. Oncol. Lett. 18, 449–455 (2019).
pubmed: 31289516 pmcid: 6540262
Denkert, C. et al. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy. Lancet Oncol. 19, 40–50 (2018).
pubmed: 29233559 doi: 10.1016/S1470-2045(17)30904-X
Loi, S. et al. Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial. Ann. Oncol. 25, 1544–1550 (2014).
pubmed: 24608200 doi: 10.1093/annonc/mdu112
Loi, S. et al. Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02–98. J. Clin. Oncol. 31, 860–867 (2013).
pubmed: 23341518 doi: 10.1200/JCO.2011.41.0902
Adams, S. et al. Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199. J. Clin. Oncol. 32, 2959–2966 (2014).
pubmed: 25071121 pmcid: 4162494 doi: 10.1200/JCO.2013.55.0491
Dieci, M. V. et al. Prognostic value of tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer: a retrospective multicenter study. Ann. Oncol. 25, 611–618 (2014).
pubmed: 24401929 pmcid: 3933248 doi: 10.1093/annonc/mdt556
Goel, S. et al. CDK4/6 inhibition triggers anti-tumour immunity. Nature 548, 471–475 (2017).
pubmed: 28813415 pmcid: 5570667 doi: 10.1038/nature23465
Wagner, J. et al. A single-cell atlas of the tumor and immune ecosystem of human breast cancer. Cell 177, 1330–1345 e1318 (2019).
pubmed: 30982598 pmcid: 6526772 doi: 10.1016/j.cell.2019.03.005
Azizi, E. et al. Single-cell map of diverse immune phenotypes in the breast tumor microenvironment. Cell 174, 1293–1308 e1236 (2018).
pubmed: 29961579 pmcid: 6348010 doi: 10.1016/j.cell.2018.05.060
Savas, P. et al. Single-cell profiling of breast cancer T cells reveals a tissue-resident memory subset associated with improved prognosis. Nat. Med. 24, 986–993 (2018).
pubmed: 29942092 doi: 10.1038/s41591-018-0078-7
Egelston, C. A. et al. Human breast tumor-infiltrating CD8(+) T cells retain polyfunctionality despite PD-1 expression. Nat. Commun. 9, 4297 (2018).
pubmed: 30327458 pmcid: 6191461 doi: 10.1038/s41467-018-06653-9
Kumar, B. V. et al. Human tissue-resident memory T cells are defined by core transcriptional and functional signatures in lymphoid and mucosal sites. Cell Rep. 20, 2921–2934 (2017).
pubmed: 28930685 pmcid: 5646692 doi: 10.1016/j.celrep.2017.08.078
Duhen, T. et al. Co-expression of CD39 and CD103 identifies tumor-reactive CD8 T cells in human solid tumors. Nat. Commun. 9, 2724 (2018).
pubmed: 30006565 pmcid: 6045647 doi: 10.1038/s41467-018-05072-0
Simoni, Y. et al. Bystander CD8(+) T cells are abundant and phenotypically distinct in human tumour infiltrates. Nature 557, 575–579 (2018).
pubmed: 29769722 doi: 10.1038/s41586-018-0130-2
Ganesan, A. P. et al. Tissue-resident memory features are linked to the magnitude of cytotoxic T cell responses in human lung cancer. Nat. Immunol. 18, 940–950 (2017).
pubmed: 28628092 pmcid: 6036910 doi: 10.1038/ni.3775
Djenidi, F. et al. CD8+CD103+ tumor-infiltrating lymphocytes are tumor-specific tissue-resident memory T cells and a prognostic factor for survival in lung cancer patients. J. Immunol. 194, 3475–3486 (2015).
pubmed: 25725111 doi: 10.4049/jimmunol.1402711
Brummelman, J. et al. High-dimensional single cell analysis identifies stem-like cytotoxic CD8(+) T cells infiltrating human tumors. J. Exp. Med. 215, 2520–2535 (2018).
pubmed: 30154266 pmcid: 6170179 doi: 10.1084/jem.20180684
Chevrier, S. et al. An immune atlas of clear cell renal cell carcinoma. Cell 169, 736–749 e718 (2017).
pubmed: 28475899 pmcid: 5422211 doi: 10.1016/j.cell.2017.04.016
Wang, Z. Q. et al. CD103 and intratumoral immune response in breast cancer. Clin. Cancer Res. 22, 6290–6297 (2016).
pubmed: 27267849 doi: 10.1158/1078-0432.CCR-16-0732
van Montfoort, N. et al. NKG2A blockade potentiates CD8 T cell immunity induced by cancer vaccines. Cell 175, 1744–1755 e1715 (2018).
pubmed: 30503208 pmcid: 6354585 doi: 10.1016/j.cell.2018.10.028
Clarke, J. et al. Single-cell transcriptomic analysis of tissue-resident memory T cells in human lung cancer. J. Exp. Med. 216, 2128–2149 (2019).
pubmed: 31227543 pmcid: 6719422 doi: 10.1084/jem.20190249
Gautam, S. et al. The transcription factor c-Myb regulates CD8(+) T cell stemness and antitumor immunity. Nat. Immunol. 20, 337–349 (2019).
pubmed: 30778251 pmcid: 6489499 doi: 10.1038/s41590-018-0311-z
Doedens, A. L. et al. Molecular programming of tumor-infiltrating CD8+ T cells and IL15 resistance. Cancer Immunol. Res. 4, 799–811 (2016).
pubmed: 27485135 pmcid: 5010943 doi: 10.1158/2326-6066.CIR-15-0178
Kuwahara, M. et al. The transcription factor Sox4 is a downstream target of signaling by the cytokine TGF-beta and suppresses T(H)2 differentiation. Nat. Immunol. 13, 778–786 (2012).
pubmed: 22751141 pmcid: 3477402 doi: 10.1038/ni.2362
Kecha, O. et al. Involvement of insulin-like growth factors in early T cell development: a study using fetal thymic organ cultures. Endocrinology 141, 1209–1217 (2000).
pubmed: 10698198 doi: 10.1210/endo.141.3.7360
Zhang, L. & Romero, P. Metabolic control of CD8(+) T cell fate decisions and antitumor immunity. Trends Mol. Med. 24, 30–48 (2018).
pubmed: 29246759 doi: 10.1016/j.molmed.2017.11.005
Banerjee, A. et al. Lack of p53 augments antitumor functions in cytolytic T cells. Cancer Res. 76, 5229–5240 (2016).
pubmed: 27466285 pmcid: 5026612 doi: 10.1158/0008-5472.CAN-15-1798
Pearce, E. L. et al. Enhancing CD8 T-cell memory by modulating fatty acid metabolism. Nature 460, 103–107 (2009).
pubmed: 19494812 pmcid: 2803086 doi: 10.1038/nature08097
Muller, D. N., Wilck, N., Haase, S., Kleinewietfeld, M. & Linker, R. A. Sodium in the microenvironment regulates immune responses and tissue homeostasis. Nat. Rev. Immunol. 19, 243–254 (2019).
pubmed: 30644452 doi: 10.1038/s41577-018-0113-4
Eil, R. et al. Ionic immune suppression within the tumour microenvironment limits T cell effector function. Nature 537, 539–543 (2016).
pubmed: 27626381 pmcid: 5204372 doi: 10.1038/nature19364
Sim, J. H. et al. Differentially expressed potassium channels are associated with function of human effector memory CD8(+) T cells. Front. Immunol. 8, 859 (2017).
pubmed: 28791017 pmcid: 5522836 doi: 10.3389/fimmu.2017.00859
Curtis, C. et al. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature 486, 346–352 (2012).
pubmed: 22522925 pmcid: 3440846 doi: 10.1038/nature10983
Alvisi, G. et al. IRF4 instructs effector Treg differentiation and immune suppression in human cancer. J. Clin. Investig. 130, 3137–3150 (2020).
pubmed: 32125291 pmcid: 7260038 doi: 10.1172/JCI130426
Pan, H. et al. 20-year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years. N. Engl. J. Med. 377, 1836–1846 (2017).
pubmed: 29117498 pmcid: 5734609 doi: 10.1056/NEJMoa1701830
Galletti, G. et al. Two subsets of stem-like CD8(+) memory T cell progenitors with distinct fate commitments in humans. Nat. Immunol. 21, 1552–1562 (2020).
pubmed: 33046887 pmcid: 7610790 doi: 10.1038/s41590-020-0791-5
Tallon de Lara, P. et al. CD39(+)PD-1(+)CD8(+) T cells mediate metastatic dormancy in breast cancer. Nat. Commun. 12, 769 (2021).
pubmed: 33536445 pmcid: 7859213 doi: 10.1038/s41467-021-21045-2
Brummelman, J. et al. Development, application and computational analysis of high-dimensional fluorescent antibody panels for single-cell flow cytometry. Nat. Protoc. 14, 1946–1969 (2019).
pubmed: 31160786 doi: 10.1038/s41596-019-0166-2
Lugli, E., Zanon, V., Mavilio, D. & Roberto, A. FACS analysis of memory T lymphocytes. Methods Mol. Biol. 1514, 31–47 (2017).
pubmed: 27787790 doi: 10.1007/978-1-4939-6548-9_3
Satija, R., Farrell, J. A., Gennert, D., Schier, A. F. & Regev, A. Spatial reconstruction of single-cell gene expression data. Nat. Biotechnol. 33, 495–502 (2015).
pubmed: 25867923 pmcid: 4430369 doi: 10.1038/nbt.3192
Dobin, A. et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics 29, 15–21 (2013).
pubmed: 23104886 doi: 10.1093/bioinformatics/bts635
Robinson, M. D., McCarthy, D. J. & Smyth, G. K. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics 26, 139–140 (2010).
pubmed: 19910308 doi: 10.1093/bioinformatics/btp616
Cerami, E. et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2, 401–404 (2012).
pubmed: 22588877 doi: 10.1158/2159-8290.CD-12-0095

Auteurs

Agnese Losurdo (A)

Laboratory of Translational Immunology, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy. agnese.losurdo@cancercenter.humanitas.it.
Medical Oncology and Hematology Unit, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy. agnese.losurdo@cancercenter.humanitas.it.

Caterina Scirgolea (C)

Laboratory of Translational Immunology, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy.

Giorgia Alvisi (G)

Laboratory of Translational Immunology, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy.

Jolanda Brummelman (J)

Laboratory of Translational Immunology, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy.

Valentina Errico (V)

Breast Surgery Unit, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy.

Luca Di Tommaso (L)

Department of Pathology, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy.
Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy.

Karolina Pilipow (K)

Laboratory of Translational Immunology, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy.

Federico Simone Colombo (FS)

Humanitas Flow Cytometry Core, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy.

Bethania Fernandes (B)

Department of Pathology, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy.

Clelia Peano (C)

Genomic Unit, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy.
Institute of Genetic and Biomedical Research, UoS Milan, National Research Council, Rozzano, Milan, Italy.

Alberto Testori (A)

Breast Surgery Unit, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy.

Corrado Tinterri (C)

Breast Surgery Unit, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy.

Massimo Roncalli (M)

Department of Pathology, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy.
Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy.

Armando Santoro (A)

Medical Oncology and Hematology Unit, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy.
Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy.

Emilia Maria Cristina Mazza (EMC)

Laboratory of Translational Immunology, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy.

Enrico Lugli (E)

Laboratory of Translational Immunology, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy. enrico.lugli@humanitasresearch.it.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH